

“PRINCIPLES OF CLINICAL PHARMACOLOGY” COURSE**2009-2010 SCHEDULE**

**All sessions will meet Thursday evenings from 6:30 p.m. to approximately 7:45 p.m. in the NIH Clinical Center, Building 10, in the Lipsett Amphitheater in Bethesda, Maryland.
Course Web Site: <http://www.cc.nih.gov/training/training/principles.html>**

September 3rd Introduction to course Lertora (NIH CC)

MODULE 1: PHARMACOKINETICS:

September 10th	Clinical pharmacokinetics	J. Lertora (NIH CC)
September 17th	Chemical assay of drugs and drug metabolites	S. Markey (NIH NIMH)
September 24th	Compartmental analysis of drug distribution	J. Lertora (NIH CC)
October 1st	Drug absorption and bioavailability	J. Lertora (NIH CC)
October 8th	Use of positron emission tomography (PET) in pharmacokinetics	R. Innis (NIH NIMH)
October 15th	Effects of renal disease on pharmacokinetics	J. Lertora (NIH CC)
October 22nd	SPECIAL LECTURE: Pharmacokinetics in patients requiring renal replacement therapy	A. Atkinson (Northwestern Un.) and G. Susla (MedImmune, Inc.)
October 29th	Noncompartmental vs. compartmental approaches to PK analysis	P. Vicini (Pfizer, Inc.)
November 5th	Effects of liver disease on pharmacokinetics	J. Lertora (NIH CC)
November 12th	Population pharmacokinetics	R. Miller (Pfizer, Inc.)

MODULE 2: DRUG METABOLISM AND TRANSPORT:

November 19th	Pathways of drug metabolism	S. Markey (NIH NIMH)
December 3rd	Drug Interactions	S. Penzak (NIH CC)
December 10th	Pharmacogenomics	D. Flockhart (IUPUI)
December 17th	Biochemical mechanisms of drug toxicity	L. Pohl (NIH NHLBI)
January 7th	SPECIAL LECTURE: P-glycoprotein and drug transport	M. Gottesman (NIH OIR) and R. Innis (NIH NIMH)
January 14th	Equilibrative and concentrative drug transport	J. Ware (Genentech, Inc.)

MODULE 3: ASSESSMENT OF DRUG EFFECTS:

January 21st	Disease progression models and clinical trial simulation	D. Mould (Projections Research, Inc.)
January 28th	Dose response and concentration response analysis	J. Lertora (NIH CC)
February 4th	Physiological and laboratory markers of drug effect	J. Woodcock (FDA)

MODULE 4: OPTIMIZING AND EVALUATING PATIENT THERAPY:

February 11th	Drug therapy in pregnant and nursing women	M. Fredericksen (Northwestern Un.)
February 18th	Developmental and pediatric pharmacology	J. van den Anker (Children's National Medical Center)
February 25th	Drug therapy in the elderly	D. Abernethy (U.S. Pharmacopeia)
March 4th	Quality assessment of drug therapy	C. Daniels (UCSD)
March 11th	Clinical analysis of adverse drug reactions	C. Chamberlain (NIH CC)

MODULE 5: DRUG DISCOVERY AND DEVELOPMENT:

March 18th	Drug discovery	E. Sausville (Un. of Maryland Medical System)
March 25th	Pre-clinical drug development	C. Takimoto (Centocor R&D, Inc./Johnson & Johnson)
April 1st	Animal scale up and Phase I studies	R. Dedrick (NIH NIBIB) and J. Collins (NCI NIH)
April 8th	Role of the FDA in guiding drug development	C. Peck (CDDS, UCSF)
April 15th	Design of clinical drug development programs	C. Breder (FDA)
April 22nd	Development of biotechnology products and large molecules	P. Garzone (PD3G Consulting)